This site uses cookies to ensure the best viewing experience for our readers.
Cancer Treatment Company KAHR Medical Raises $18 Million

Cancer Treatment Company KAHR Medical Raises $18 Million

The company intends to use the funding to advance its immuno-oncology drug candidates, especially its lead product, DSP107, tested for the treatment of solid tumors

CTech | 14:17  25.02.2020
Jerusalem-based biopharma company KAHR Medical Ltd. has raised $18 million, the company announced Tuesday. The round was led by Flerie Invest AB, Oriella Ltd., Hadasit Bio-Holdings Ltd., a biotechnology company owned by the Hadassah University Hospital in Jerusalem, Pavilion Capital Pte Ltd., and Mirae Asset Venture Investment Co. Ltd.

KAHR Medical was founded in 2015 and has raised $30.11 million prior to this round, according to Pitchbook data.

 KAHR Medical CEO Yaron Pereg. Photo: KAHR Medical KAHR Medical CEO Yaron Pereg. Photo: KAHR Medical  KAHR Medical CEO Yaron Pereg. Photo: KAHR Medical

KAHR Medical intends to use the funding to advance its immuno-oncology drug candidates, especially its lead product, DSP107, which works by targeting CD47, a protein that is overexpressed by cancer cells and emits a signal that enables them to evade an immune response. The company is testing DSP107 for the treatment of solid tumors.
share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS